EyePoint Pharma rises on eye disease drug trial data

EyePoint

05/02/2025 15:18

** Shares of drugmaker EyePoint Pharmaceuticals  EYPT.O 
rise ~11% to $8.47
    ** EYPT says its drug, Duravyu, met the main goal in
mid-stage trial for the treatment of diabetic macular edema, a
condition where fluid builds up in the central part of the
retina due to damaged blood vessels
    ** The main goal was to evaluate if the drug could reduce
the frequency of injections needed to treat the condition
compared to the standard treatment, aflibercept
    ** 2.7 mg dose of Duravyu helped 73% of patients avoid extra
injections, compared to 50% of patients treated with aflibercept
- EYPT
    ** Co plans to initiate a late-stage non-inferiority trial
for the drug by the end of 2025
    ** EYPT fell ~67% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))